Search

everythinglearnresearchcommunity

for

Search:↓

Upadacitinib effectively treats severe alopecia areata and is safe.

Scientists made antibodies to tell cashmere and wool apart, which could improve how we identify animal fibers.

Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.

PRP treatment may help with alopecia areata, especially in newer cases.

Apremilast did not work for treating severe alopecia areata.

Many patients with Alopecia Areata have underlying autoimmune disorders, especially thyroid issues.

People with alopecia areata have higher insulin resistance.

Hepatitis B virus exposure may be linked to increased risk of alopecia areata.

There is no significant link between alopecia areata and the PON1 enzyme polymorphisms studied.

Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.

Mirror-image twins can have alopecia areata on opposite sides of their heads.

Alopecia areata and myasthenia gravis can occur as rare symptoms of breast cancer.

Antibody treatments show promise for hair loss but need more research.

SADBE treatment led to complete hair regrowth in mice with alopecia areata by altering immune cell movement.

The Peripilar sign does not indicate perifollicular infiltrate in hair loss from Androgenetic Alopecia.

Men with male pattern baldness have lower levels of the antioxidant PON1.

Baricitinib helps with early hair regrowth in people with alopecia areata.

The young goat had anaplasmosis and copper deficiency.

Anti-SRP myopathy can be linked to systemic lupus erythematosus and may improve with specific treatment.

Baricitinib is a promising treatment for alopecia areata.

Hair loss in male pattern baldness is linked to changes in immune cell behavior around hair follicles.

Paraproteinemic keratopathy can show eye symptoms before other signs of disease, needing careful treatment and long-term follow-up.

Some multiple sclerosis treatments may trigger hair loss conditions like alopecia areata.

Patients and doctors often agree on the severity of eyebrow and eyelash hair loss in severe alopecia areata.

People with alopecia areata have higher levels of a heart disease marker in their blood.

Melanocytes might be targeted by the immune system in people with alopecia areata, but more research is needed.

Higher levels of retinol-binding protein 4 are found in people with alopecia areata, but these levels don't relate to how severe the condition is.

Baricitinib was effective in treating alopecia areata in two major trials.

Upadacitinib can effectively regrow hair in alopecia areata patients without worsening sarcoidosis.

Men with male pattern baldness have higher levels of A-FABP, which might help in early detection.